



(51) International Patent Classification:

C07C 43/225 (2006.01) **A61K 31/381** (2006.01)
C07C 43/23 (2006.01) **A61P 3/04** (2006.01)
C07C 43/247 (2006.01) **A61P 3/10** (2006.01)
C07C 43/253 (2006.01) **A61P 35/00** (2006.01)
C07D 231/20 (2006.01) **A61P 29/00** (2006.01)
C07D 333/16 (2006.01) **A61P 31/00** (2006.01)
A61K 31/085 (2006.01) **A61P 31/12** (2006.01)
A61K 31/415 (2006.01)

(21) International Application Number:

PCT/EP2012/060050

(22) International Filing Date:

29 May 2012 (29.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11305645.1 26 May 2011 (26.05.2011) EP

(71) Applicant (for all designated States except US): **TF-CHEM** [FR/FR]; Pharma Parc II, Voie de l'Innovation, Batiment C, F-27100 Val De Reuil (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DELIEN-COURT-GODEFROY, Géraldine** [FR/FR]; 40-44 rue de l'Eglise, F-76160 Bois d'Ennebourg (FR). **LOPES, Lénaïg** [FR/FR]; 132A rue du Président Kennedy, F-76140 Le Petit Quevilly (FR).(74) Agent: **AHNER, Francis**; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS



(57) **Abstract:** The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin.